HomeSGX-LISTED COMPANIESSpindex Industries FY2025 Full Year Financial Statement

Spindex Industries FY2025 Full Year Financial Statement

Published on

spot_img

Spindex Industries Limited experienced a volatile FY2025, where a slight increase in full-year revenue was observed despite a decline in the second half across all business sectors. Profitability was significantly impacted by a substantial rise in administrative expenses, driven by foreign exchange losses and impairment charges. Despite these challenges, the Group maintained a strong financial position, bolstered by increased cash and strategic investments, including an acquisition, positioning it to navigate ongoing economic uncertainties and tariff issues.

• Explore how a dynamic global economic landscape presented significant challenges to the Group’s financial results this year

• Uncover strategic moves, including an acquisition and investments in operational efficiency, aimed at bolstering the Group’s future growth

• Understand the key drivers behind a notable increase in administrative costs and a significant shift in overall profitability

LISTEN TO THE PODCAST BELOW:

Latest articles

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...

AstraZeneca deploys AI to cut drug timelines by 30% and boost survival

AstraZeneca is stepping up its investment in AI drug discovery to shorten treatment timelines...

More like this

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...